Role of phospholipid transfer protein in high-density lipoprotein-mediated reverse cholesterol transport

Current Atherosclerosis Reports

Volumn 13, Issue 3, 2011, Pages 242-248

  Yazdanyar, Amirfarbod ^a   Yeang, Calvin ^a   Jiang, Xian Cheng ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cholesterol efflux; High Density Lipoprotein (HDL); Phospholipid Transfer Protein (PLTP); Reverse Cholesterol Transport (RCT)

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID TRANSFER PROTEIN; SCAVENGER RECEPTOR BI;

ATHEROSCLEROSIS; CELL TRANSPORT; CHOLESTEROL TRANSPORT; GENE OVEREXPRESSION; HUMAN; LIPID OXIDATION; LIPOPROTEIN METABOLISM; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSPORT KINETICS;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; HUMANS; LIPID METABOLISM; LIVER; MACROPHAGES; MEMBRANE PROTEINS; MICE; PHOSPHOLIPID TRANSFER PROTEINS; PHOSPHOLIPIDS; PROTEIN BINDING;

EID: 79955928267     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-011-0172-5     Document Type: Review

References (73)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-9. (Pubitemid 23132154)
2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Investig. 1991;88:1785-92.
3. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Investig. 1989;84:1086-95. (Pubitemid 19247577)
4. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551-61.
5. Williams KJ, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol. 1998;9:471-4. (Pubitemid 28495557)
6. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832-44. (Pubitemid 350287108)
7. Nievelstein PF, Fogelman AM, Mottino G, Frank JS. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue. Arterioscler Thromb. 1991;11:1795-805.
8. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365-75.
9. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol. 2010;30:139-43.
10. Ye D, Lammers B, Zhao Y, Meurs I, Van Berkel T, Van Eck M. ATP-Binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis. Curr Drug Targets. 2010.
11. Wang X, Rader DJ. Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol. 2007;22:368-72. (Pubitemid 46897290)
12. Calabresi L, Franceschini G. Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. Trends Cardiovasc Med. 2010;20:50-3.
13. Masson D, Jiang XC, Lagrost L, Tall AR. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res. 2009;50(Suppl):S201-6.
14. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-20.
15. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-28.
16. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 2006;113:2548-55.
17. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21:13-27.
18. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem. 2008;54:788-800. (Pubitemid 351671595)
19. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008;263:256-73. (Pubitemid 351207349)
20. Marcel YL, Ouimet M, Wang MD. Regulation of cholesterol efflux from macrophages. Curr Opin Lipidol. 2008;19:455-61.
21. Wang N, Tall AR. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:1178-84. (Pubitemid 36871270)
22. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005;1:121-31. (Pubitemid 43977167)
23. Jessup W, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol. 2006;17:247-57. (Pubitemid 43786058)
24. Silver DL, Wang N, Xiao X, Tall AR. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J Biol Chem. 2001;276:25287-93.
25. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-32. (Pubitemid 40962099)
26. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751-6. (Pubitemid 37498976)
27. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Highdensity lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987-94.
28. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res. 2001;42:1308-17. (Pubitemid 32744255)
29. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853-7. (Pubitemid 32691642)
30. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352-64. (Pubitemid 43948059)
31. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond). 2009;116:87-98.
32. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol. 2010;21:229-38.
33. Albers JJ, Cheung MC. Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. Curr Opin Lipidol. 2004;15:255-60. (Pubitemid 38716557)
34. Bruce C, Beamer LJ, Tall AR. The implications of the structure of the bactericidal/permeability-increasing protein on the lipidtransfer function of the cholesteryl ester transfer protein. Curr Opin Struct Biol. 1998;8:426-34. (Pubitemid 28409950)
35. Massey JB, Hickson D, She HS, Sparrow JT, Via DP, Gotto Jr AM, et al. Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. Biochim Biophys Acta. 1984;794:274-80. (Pubitemid 14098832)
36. Kawano K, Qin SC, Lin M, Tall AR, Jiang XC. Cholesteryl ester transfer protein and phospholipid transfer protein have nonoverlapping functions in vivo. J Biol Chem. 2000;275:29477-81. (Pubitemid 32043823)
37. Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer Jr HB. Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem. 1997;272:27393-400. (Pubitemid 27452707)
38. Yang XP, Yan D, Qiao C, Liu RJ, Chen JG, Li J, et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol. 2003;23:1601-7. (Pubitemid 37108204)
39. van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol. 2000;20:1082-8.
40. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Investig. 1999;103:907-14. (Pubitemid 29152637)
41. Qin S, Kawano K, Bruce C, Lin M, Bisgaier C, Tall AR, et al. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J Lipid Res. 2000;41:269-76. (Pubitemid 30117868)
42. Yan D, Navab M, Bruce C, Fogelman AM, Jiang XC. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res. 2004;45:1852-8.
43. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol. 2002;13:135-9.
44. Schlitt A, Bickel C, Thumma P, Blankenberg S, Rupprecht HJ, Meyer J, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2003;23:1857-62. (Pubitemid 37254875)
45. Cavusoglu E, Marmur JD, Chhabra S, Chopra V, Eng C, Jiang XC. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. Atherosclerosis. 2009;207:261-5.
46. Chen X, Sun A, Mansoor A, Zou Y, Ge J, Lazar JM, et al. Plasma PLTP activity is inversely associated with HDL-C levels. Nutr Metab (Lond). 2009;6:49.
47. Yatsuya H, Tamakoshi K, Hattori H, Otsuka R, Wada K, Zhang H, et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ J. 2004;68:11-6. (Pubitemid 38139930)
48. Schgoer W, Mueller T, Jauhiainen M, Wehinger A, Gander R, Tancevski I, et al. Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis. 2008;196:219-26.
49. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41:56-65.
50. Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Investig. 1996;98:2373-80. (Pubitemid 26394213)
51. Valenta DT, Bulgrien JJ, Bonnet DJ, Curtiss LK. Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency. J Lipid Res. 2008;49:24-32.
52. Oram JF, Wolfbauer G, Vaughan AM, Tang C, Albers JJ. Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem. 2003;278:52379-85. (Pubitemid 38035828)
53. Wolfbauer G, Albers JJ, Oram JF. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim Biophys Acta. 1999;1439:65-76. (Pubitemid 29296864)
54. Curtiss LK, Valenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol. 2006;26:12-9.
55. Vikstedt R, Ye D, Metso J, Hildebrand RB, Van Berkel TJ, Ehnholm C, et al. Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler Thromb Vasc Biol. 2007;27:578-86.
56. Desrumaux CM, Mak PA, Boisvert WA, Masson D, Stupack D, Jauhiainen M, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res. 2003;44:1453-61. (Pubitemid 37279589)
57. O'Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation. 2003;108:270-4. (Pubitemid 36899015)
58. Lee-Rueckert M, Vikstedt R, Metso J, Ehnholm C, Kovanen PT, Jauhiainen M. Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells. J Lipid Res. 2006;47:1725-32. (Pubitemid 44222823)
59. Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol Cell Biol. 2003;23:2182-91. (Pubitemid 36278826)
60. Liu R, Hojjati MR, Devlin CM, Hansen IH, Jiang XC. Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:190-6. (Pubitemid 46360398)
61. Jiang XC, Tall AR, Qin S, Lin M, Schneider M, Lalanne F, et al. Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem. 2002;277:31850-6. (Pubitemid 34968992)
62. Ogier N, Klein A, Deckert V, Athias A, Bessede G, Le Guern N, et al. Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol supplementation. Arterioscler Thromb Vasc Biol. 2007;27:2407-12. (Pubitemid 350203957)
63. Jiang XC, Li Z, Liu R, Yang XP, Pan M, Lagrost L, et al. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem. 2005;280:18336-40. (Pubitemid 41389080)
64. Cao G, Beyer TP, Yang XP, Schmidt RJ, Zhang Y, Bensch WR, et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem. 2002;277:39561-5. (Pubitemid 35190935)
65. van Haperen R, Samyn H, Moerland M, van Gent T, Peeters M, Grosveld F, et al. Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis. PLoS One. 2008;3:e2255. This article showed that macrophage PLTP expression has a proatherogenic property.
66. Oram JF, Wolfbauer G, Tang C, Davidson WS, Albers JJ. An amphipathic helical region of the N-terminal barrel of phospholipid transfer protein is critical for ABCA1-dependent cholesterol efflux. J Biol Chem. 2008;283:11541-9. This article showed the interaction of PLTP and ABCA1.
67. Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res. 2000;41:1651-7.
68. Murdoch SJ, Wolfbauer G, Kennedy H, Marcovina SM, Carr MC, Albers JJ. Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. J Lipid Res. 2002;43:281-9. (Pubitemid 34184015)
69. Vikstedt R, Metso J, Hakala J, Olkkonen VM, Ehnholm C, Jauhiainen M. Cholesterol efflux from macrophage foam cells is enhanced by active phospholipid transfer protein through generation of two types of acceptor particles. Biochemistry. 2007;46:11979-86. (Pubitemid 47623766)
70. Moerland M, Samyn H, van Gent T, Jauhiainen M, Metso J, van Haperen R, et al. Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice. J Lipid Res. 2007;48:2622-31. (Pubitemid 350272847)
71. Samyn H, Moerland M, van Gent T, van Haperen R, Grosveld F, van Tol A, et al. Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Atherosclerosis. 2009;204:429-34. This is the first article to show that elevation of systemic PLTP impairs RCT in vivo.
72. de Vries R, Groen AK, Perton FG, Dallinga-Thie GM, van Wijland MJ, Dikkeschei LD, et al. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis. 2008;196:733-41.
73. Attia N, Nakbi A, Smaoui M, Chaaba R, Moulin P, Hammami S, et al. Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol efflux in type 2 diabetic subjects with coronary artery disease. Tohoku J Exp Med. 2007;213:129-37. (Pubitemid 47554873)